The efficacy of fluconazole in treating prosthetic valve endocarditis caused by Candida glabrata : report of a case

• Published in: Surgery today (Tokyo, Japan) Japan), 1994-01, Vol.24 (7), p.651-654
• Main Authors: NISHIDA, T, MAYUMI, H, KAWACHI, Y, TOKUNAGA, S, MARUYAMA, Y, NAKASHIMA, A, YASUI, H, TOKUNAGA, K
• Format: Article
• Language: English
• Subjects: Aged; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antifungal agents; Aortic Valve Insufficiency - surgery; Biological and medical sciences; Candidiasis - drug therapy; Endocarditis - drug therapy; Endocarditis - microbiology; Fluconazole - therapeutic use; Heart Valve Prosthesis - adverse effects; Humans; Male; Medical sciences; Mitral Valve Insufficiency - surgery; Pharmacology. Drug treatments; Prosthesis-Related Infections - drug therapy; Prosthesis-Related Infections - microbiology; Treatment Outcome
• ISSN: 0941-1291; 1436-2813
• DOI: 10.1007/BF01833735

A case of active prosthetic valve infective endocarditis (PVE) due to Candida glabrata was successfully treated by the systemic administration of fluconazole. A 66-year-old Japanese man with infective endocarditis of unknown etiology underwent aortic and mitral valve replacement to treat severe aortic and mitral regurgitation associated with multiple organ failure. Postsurgical cultures of arterial blood were repeatedly positive for C. glabrata, and therefore fluconazole was administered either intravenously or orally at a dose of 400 mg/day for 46 days. During that time the signs of inflammation including fever such as an elevated white blood cell count and the presence of C-reactive protein (CRP) all improved while the blood cultures became negative. Fluconazole is thus considered to be effective in treating PVE caused by C. glabrata. When administering this treatment, it is also important to monitor the patient's renal and liver function.